Comparison · NCT00114972-256f3397
CABG vs PCI With DES: Repeat Revascularization (PCI and/or CABG).
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. CABG vs PCI With DES: Repeat Revascularization (PCI and/or CABG). Trial comparisons, record NCT00114972-256f3397. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00114972-256f3397
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0589 | 0.045 | 0.0768 | wilson | |
| Risk in group 2 | 0.135 | 0.114 | 0.159 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0758 | -0.104 | -0.0483 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.437 | 0.319 | 0.6 | log | |
| Odds ratio, group 1 over group 2 | 0.402 | 0.285 | 0.567 | log | |
| Number needed to treat, for one fewer participant with the outcome on CABG than on PCI With DES | 13.2 | 9.66 | 20.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | CABG | Coronary Artery By-pass Graft (CABG) | 50 | 849 | OG000 |
| Group 2 | PCI With DES | Percutaneous coronary intervention (PCI) using TAXUS Express Drug Eluting Stent (DES) | 120 | 891 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Repeat Revascularization (PCI and/or CABG).
- Description
- Number of participants with repeat revascularization (PCI and/or CABG).
- Time frame
- 12 Months post enrollment
- Population
Source ClinicalTrials.gov
Trial
- Title
- SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries
- NCT number
- NCT00114972
- Phases
- PHASE3
- Conditions
- Coronary Artery Disease
- Interventions
- Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent, Coronary Artery Bypass Surgery
- Lead sponsor
- Boston Scientific Corporation
- Results first posted
- 2010-06-23
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00114972?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00114972-256f3397